Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Oxyrane (Netherlands) a clinical-stage biopharmaceutical focused on enzyme replacement therapies for Pompe’s a lysosomal storage disease, closed a $26.5M Series D financing. Participants include Forbion Capital Partners, Morningside Group and New Science Ventures.

Neuraltus Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on small molecule drugs for the neurodegenerative diseases such as ALS multiple sclerosis, Parkinson’s, Alzheimer’s, Fabry’s and Gaucher’s diseases, closed a $9.6M Series B financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Synageva BioPharma (Lexington, MA) a clinical-stage biopharma focused on rare diseases and orphan therapeutics for the treatment of lysosomal storage disease and metabolic disorders, closed a $25M Series C financing. Participants have included New Leaf Venture Partners, Hunt BioVentures, Yasuda Enterprise Development, Baker Brothers Investments, Tullis Dickerson and Four Partners.

Helix Therapeutics (New Haven, CT) a preclinical-stage company developing triplex-forming oligonucleotides to target genome modification with a focused on hemoglobin, immune and lysosomal storage disorders, closed a $2.5M Series A financing. Participants include Canaan Partners and Connecticut Innovations.

Vivendy Therapeutics (Switzerland) developer of an enzyme replacement therapy for morbus morquio, a rare lysosomal storage disease closed a $15.5M Series A financing. Participants include BioMedInvest, LSP Life Sciences Partners and TVM Capital.

  

to top of page...